Olivier Elemento

TL;DR: This study provides the first comprehensive characterization of methylome in ALCL and examines whether a treatment with the 5-azacytidine (5-Aza) could reverse the hypermethylation profile of ALCL PDTX.

TL;DR: It is shown that cabozaninib eradicates poorly differentiated invasive cancer that develop in the context of prostate-specific PTEN and p53 loss, respectively, within 48 hours of cabozantinib treatment, and suggest the possibility of combination therapies of Cabozant inib with T-cell checkpoint blockade or vaccine-based approaches, to augment immunologic responses in advanced cancers.

TL;DR: These data demonstrate how histone 3 lysine-to-methionine mutations can be used to uncover critical roles for methyltransferases and identify FOXD1 as a top target of PRC2 that is silenced in melanocytes and found that aberrant overexpression ofFOXD1 accelerated melanoma onset.

TL;DR: ERBB2 is a frequent mutation at different stages of UC, and in higher stage disease, clonal selection of the S310F/Y hot-spot mutation may occur and requires further study.

TL;DR: Having proven that JAK/STAT signaling pathway plays a key role in both ALK+ and ALK - ALCL, the expression of BlackMamba could be modulated after treatment with JAK1/2 (ruxolitinib) TKi is tested and found the physical interaction with the histone-lysine N-methyltransferase enzyme EZH2 by RIP in the FedP cells.